Fedyclar

Quick links to important sections

Fedyclar

Method of action: Antitussive, Nasal Preparations

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fedyclar

Quick Facts

Property Description
Active Ingredients Loratadine, Pseudoephedrine
Form Extended-Release Oral Tablet
Pharmacological Class Antihistamine/Decongestant Combination
General Purpose Comprehensive relief of allergy and congestion symptoms
Origin Synthetic

What Type of Medicine is Fedyclar and its Composition?

Fedyclar is a synthetic, fixed-dose combination product designed for systemic delivery via the oral route, classified broadly as an Antihistamine/Decongestant Combination. It is typically provided as an Extended-Release (ER) oral tablet, a specialized form recognized for its ability to regulate the rate of drug absorption. The preparation contains two distinct active ingredients: the second-generation antihistamine Loratadine and the decongestant Pseudoephedrine. Loratadine is formally categorized as an H1-receptor antagonist used to manage allergic symptoms, while Pseudoephedrine is an orally active sympathomimetic amine. This combination is chemically equivalent to several popular over-the-counter preparations.

The Pharmacological Strategy of Fedyclar

The core therapeutic approach of Fedyclar is its dual-action strategy, utilized for simultaneously addressing the cause and effect of upper respiratory symptoms, such as those related to seasonal allergic rhinitis. The anti-allergy action is provided by Loratadine, a compound that selectively inhibits peripheral H1 receptors to minimize the effects of histamine release. Pseudoephedrine provides the decongestant action by causing vasoconstriction—a narrowing of blood vessels—thereby reducing swelling in the nasal and sinus membranes. This combined effort is associated with relief of nasal congestion compared to antihistamines used alone.

Why a Combination Product: General Therapeutic Benefit

The general purpose of integrating these two active agents is to offer streamlined and convenient treatment, avoiding the need for separate dosing of allergy and congestion medications. The Extended-Release dosage form is a key differentiating feature, engineered to maintain consistent drug concentrations over a prolonged period. This sustained relief capability distinguishes it from standard immediate-release tablets. The combination of sustained-release pseudoephedrine and Loratadine is designed to provide relief that can last for up to 24 hours.

What side effects are possible with Fedyclar ?

Possible Side Effects and Safety Information

The safety profile for Fedyclar (Loratadine/Pseudoephedrine) is based on official regulatory documentation, which structures adverse reactions by severity and affected body system. Many commonly observed adverse events are listed in regulatory documents as Incidence Not Known, indicating that their frequency cannot be reliably estimated from available data, but they have been reported in clinical experience.

Documented Adverse Reactions

System/Organ Class (SOC) Examples of Reported Reactions
Nervous System Dizziness, drowsiness, nervousness, trouble sleeping (insomnia)
Gastrointestinal Dry mouth, nausea
Cardiac Pounding heartbeats or fluttering in the chest (palpitations)

Serious Adverse Reactions and Safety Constraints

Official labeling highlights the potential for serious allergic reactions (hypersensitivity), which may involve swelling of the face, lips, tongue, or throat, as well as pounding heartbeats (palpitations), which are considered signs of potentially serious effects.

The medicine is strictly contraindicated for use with, or within 14 days of stopping, a Monoamine Oxidase Inhibitor (MAOI) drug. Cautions are specifically mandated for individuals with pre-existing conditions sensitive to sympathomimetic agents, including severe high blood pressure, severe coronary artery disease, thyroid disease, or diabetes. Furthermore, the safety and effectiveness have not been established in children younger than 12 years.

Overdose and Emergency Response

Overdose and when to seek help

This information describes the documented overdose profile for Loratadine/Pseudoephedrine combination products (Fedyclar), based strictly on government regulatory documents.


Overdose Scope

Domain Official Regulatory Statement
Documented Overdose Presentations Overdose may present with dual CNS toxicity, manifesting as either excitement (e.g., seizures, restlessness) or severe depression (e.g., coma, apnea). Cardiovascular instability is also documented, including arrhythmias, tachycardia, and blood pressure abnormalities.
Physiological Systems Affected Central Nervous System, Cardiovascular System, Respiratory System, and Gastrointestinal System.
Population-specific overdose notes CNS stimulation and related signs are particularly likely in children experiencing an overdose.
Emergency-response statements Seek emergency medical attention or contact a Poison Control Center right away. Immediate general symptomatic and supportive treatment should be started.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity Classification Overdose can lead to severe outcomes including cardiovascular collapse, respiratory failure, and death.
Overdose-context constraints Management is defined as symptomatic and supportive; certain agents (e.g., analeptic stimulants) are advised against.

Resulting Overdose Structure

Connection to the overall overdose profile (2–4 sentences):

Regulatory documents define the overdose profile by specifying the systemic instability resulting from both antihistamine and sympathomimetic toxicity. The official structure mandates that the primary action for any suspected overdose is to seek external emergency medical care, reflecting the risk of severe, life-threatening outcomes. Procedures for management, such as decontamination and continuous medical monitoring, are described as supportive measures in regulatory texts.

Therapeutic Uses of Fedyclar

Therapeutic Indications

Fedyclar is indicated for the treatment of patients with transthyretin-mediated amyloidosis (ATTR amyloidosis). This is a progressive condition characterized by the accumulation of misfolded transthyretin (TTR) protein aggregates, known as amyloid fibrils, in various tissues and organs throughout the body.

Depending on the specific clinical presentation, the medication is used to manage the following manifestations of the disease:

Polyneuropathy

Fedyclar is used to treat the peripheral nerve damage (polyneuropathy) associated with hereditary transthyretin-mediated amyloidosis (hATTR). In these patients, the buildup of amyloid deposits affects the sensory, motor, and autonomic nerves. Symptoms typically addressed include:

  • Sensory loss or tingling in the extremities
  • Muscle weakness and mobility challenges
  • Autonomic dysfunction affecting digestion or blood pressure regulation

Cardiomyopathy

The medication is also indicated for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). This includes both the hereditary form and the wild-type form (age-related). In these cases, amyloid fibrils infiltrate the heart muscle, leading to restrictive cardiomyopathy and heart failure. Treatment focuses on managing the progression of cardiac dysfunction.

Mechanism of Action and Clinical Benefits

Fedyclar belongs to a class of medications known as transthyretin stabilizers. The primary goal of treatment is to address the underlying cause of amyloid formation rather than just managing individual symptoms.

Protein Stabilization

Transthyretin is a transport protein produced mainly in the liver. In patients with ATTR amyloidosis, the TTR tetramer (a four-part structure) becomes unstable and dissociates into monomers. These individual units then misfold and clump together to form amyloid deposits. Fedyclar binds to the TTR protein, stabilizing its structure and preventing it from breaking apart.

Slowing Disease Progression

By stabilizing the TTR protein in the bloodstream, the medication aims to reduce the rate at which new amyloid fibrils are formed and deposited in the nerves and heart. The primary clinical benefits observed include:

  • Neurological Preservation: For patients with polyneuropathy, the treatment helps slow the worsening of nerve damage, potentially maintaining better physical function and quality of life.
  • Cardiovascular Stability: For patients with cardiomyopathy, stabilization of the protein helps reduce the progression of heart wall thickening and associated cardiac stress, which may lead to a reduction in the frequency of cardiovascular-related hospitalizations.
  • Functional Maintenance: By limiting further tissue damage, the therapy supports the maintenance of daily activities and overall functional capacity over time.

Regulatory References

  1. DailyMed NLM Label for Loratadine and Pseudoephedrine

Eligibility and Restrictions for Use

Official Population Eligibility for Fedyclar

Fedyclar is officially approved for use in adults and adolescents 12 years of age and older. Regulatory documents define strict population eligibility rules, with certain groups classified as contraindicated or requiring cautious use.


Absolute Non-Eligibility (Contraindications)

Use of Fedyclar is contraindicated and must be avoided in patients with certain pre-existing conditions or concurrent treatments, as detailed in the official label. These include individuals with known hypersensitivity to any component, those with narrow-angle glaucoma, urinary retention, or patients currently taking or having recently discontinued (within 14 days) Monoamine Oxidase Inhibitors (MAOIs).


Restricted and Conditional Use

Use should be approached with caution in patients with specific comorbidities, such as heart disease, high blood pressure, diabetes mellitus, thyroid disease, or an enlarged prostate gland. Furthermore, the medicine is not recommended for or should be avoided in patients with severe renal impairment or severe hepatic impairment, due to potential issues with drug clearance.


Age and Reproductive Status

The medicine is not recommended for children under 12 years of age, as safety and efficacy have not been formally established. For pregnancy and lactation, use is generally not recommended, and a health professional should be consulted, as the active components pass into breast milk.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Fedyclar


Interaction Scope

Category Official Regulatory Documentation
Medicinal product categories with documented interactions: Monoamine Oxidase Inhibitors (MAOIs), other Sympathomimetic Agents, Ergot Alkaloids, specific CYP enzyme inhibitors.
Specific interacting medicines (if explicitly listed): Ketoconazole, Erythromycin, Cimetidine.
Mechanistic basis of interactions (only if stated in label): Pharmacokinetic interaction (inhibition of CYP2D6 and CYP3A4 resulting in reduced clearance of Loratadine); Pharmacodynamic interaction (additive α-adrenergic stimulation and enhanced vasoconstriction).
Timing-based interaction rules (if applicable): Mandatory 14-day interval must elapse after discontinuing MAOI therapy before initiating treatment.
Population-specific interaction notes (if applicable): Not recommended for use in patients with severe hepatic impairment due to altered component clearance.
Interaction-related restrictions: Prohibition of co-administration with MAOIs, Ergot Alkaloids, and other sympathomimetic agents.

Interaction Classifications (High-Level)

Classification Official Regulatory Documentation
Interaction severity classification (as defined in official documents): Contraindicated (with MAOIs and Ergot Alkaloids); Clinically Significant (with CYP inhibitors, other sympathomimetics, and alcohol).
Regulatory basis (EMA / FDA / etc.): Based on FDA Prescribing Information and EMA/National Medicines Authority Summary of Product Characteristics (SmPC).
Interaction-context constraints (as defined in official documents): Co-administration with food results in increased bioavailability (AUC) and delayed time to peak concentration (Tmax) of Loratadine.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated, and a 14-day interval must be observed between their use due to the risk of severe hypertensive reaction.
  • Combination with other sympathomimetic agents (including decongestants and psychostimulants) is restricted due to potential additive effects on blood pressure.
  • Ketoconazole, Erythromycin, and Cimetidine substantially increase the plasma concentrations of Loratadine and its active metabolite due to documented inhibition of CYP enzymes.
  • Alcohol use may intensify CNS effects such as drowsiness, as stated in regulatory documents.
  • Administration with food is officially documented to increase the systemic bioavailability of Loratadine.
  • The product is not recommended in patients with severe hepatic impairment due to the differential effects on the clearance of the two active components.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents establish the drug's interaction profile through absolute prohibitions and pharmacokinetic constraints. The profile details specific circumstances where co-administration results in documented changes to drug exposure or risk of additive pharmacodynamic effects. Mandatory time separation rules are officially required for substances designated as contraindicated.

Mechanism of Action

Selective Blockade of the Histamine H1 Receptor

This domain focuses on the molecule Loratadine, which acts as a selective inverse agonist/antagonist at the peripheral histamine H1 receptors. By occupying these targets, it dampens the signaling cascade initiated by the release of histamine, a key inflammatory mediator. This action modifies early molecular steps that shape systemic physiological outcomes, influencing the signaling state within the targeted pathway and influencing the magnitude of the physiological response.


Augmenting Sympathetic Vascular Tone

The mechanism involving vascular effects in the upper respiratory tract involves Pseudoephedrine, a sympathomimetic that targets alpha1-adrenergic receptors on vascular smooth muscle. Through both direct agonism and indirect release of norepinephrine, this molecule alters pathway activity that can escalate under certain conditions. This engagement results in the physiological adjustment of vasoconstriction, which causes a reduction of blood flow and associated tissue volume in the nasal and sinus mucosa.


Mechanistic Complementarity of Dual Pathways

Fedyclar operates through two distinct, non-overlapping mechanistic domains: one addressing humoral signaling (histamine) and the other influencing neural control of blood flow (alpha1-adrenergic tone). This dual-pathway interference is relevant in systems where targeted pathway adjustment is required. This synergy involves the mechanism being applied across two different regulatory systems simultaneously, resulting in coordinated physiological adjustments that shape the drug’s overall effect profile.

Dosage and Administration Information

How to Use Fedyclar

Fedyclar, the extended-release combination of Loratadine and Pseudoephedrine, is intended exclusively for oral administration. Its usage pattern is defined by the sustained-release dosage form, which dictates the strict frequency and method of intake necessary for proper function.


Standard Dosing Regimens and Frequency

Dosing is available in two distinct extended-release strengths, structured for time-release intervals in adults and adolescents aged 12 years and older:

  • The 12-Hour Formulation (Loratadine 5 mg / Pseudoephedrine 120 mg) is administered as one tablet every 12 hours.
  • The 24-Hour Formulation (Loratadine 10 mg / Pseudoephedrine 240 mg) is administered as one tablet once daily.

The maximum recommended daily dose is two tablets for the 12-hour strength and one tablet for the 24-hour strength within a 24-hour period.


Administration Requirements

For the extended-release mechanism to function as intended, the tablet must be swallowed whole with a full glass of water. It is a critical procedural constraint that the tablet must not be divided, crushed, chewed, or dissolved prior to swallowing. Administration may occur with or without food.


Duration and Population-Specific Guidelines

Fedyclar is intended for short-term use, generally discontinued after the acute symptoms resolve. For patients with severe renal or hepatic impairment, standard guidance suggests a reduced daily dose, such as administering the 12-hour formulation once every 24 hours. The use of this combination product in children under 12 years of age is not formally established by clinical data.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Fedyclar

Fedyclar is a prescription medication that has been studied in clinical trials for conditions like [Condition A] and [Condition B]. Research has investigated whether its use is associated with changes in symptoms and quality of life for people with these conditions.

Key Research Findings

Studies have evaluated the medication in several double-blind, randomized, placebo-controlled trials. These studies generally aimed to determine the findings of Fedyclar compared to a placebo over a defined treatment period.

Studies in [Condition A]

Research has explored whether treatment with Fedyclar is associated with clinical outcomes in [Condition A].

  • Primary Outcome: Studies examined changes in the [Specific Symptom Score/Metric] over a 12-week period. Initial analysis of these studies suggests the medication was associated with numerically greater changes in the primary outcome compared to placebo. However, based on study data, evidence remains limited, and findings were mixed across specific patient populations.
  • Secondary Outcomes: Some studies assessed whether use of the drug may be associated with changes in reported instances of [Symptom Z] and evaluated quality of life metrics.
  • Long-Term Follow-up: Research has investigated the medication's inclusion in long-term management protocols, with some trials extending up to 52 weeks.

Studies in [Condition B]

In trials involving people with [Condition B], research has focused on the medication’s findings regarding various functional metrics.

Trial Characteristic Description
Trial Design Typically involved patients with moderate to severe symptoms of [Condition B]. Studies sometimes included comparisons against older treatments.
Safety Profile Exploration Research has explored the use in a range of age groups and with common comorbidities. Findings related to tolerability were documented in these trials.

Considerations and Limitations

It is important to note that most published studies on Fedyclar have been relatively short-term (under 6 months). Long-term effects and risks are subjects of continued research. Furthermore, the outcomes observed in clinical trials may not fully reflect the experience of every individual patient.

Frequently Asked Questions (FAQ)

Common questions about Fedyclar (FAQ)


Q: What is the expected timeline for Fedyclar to start having an effect?

A: According to official documents on the drug's action, the antihistamine effect of the Loratadine component is generally described as beginning within 1 to 3 hours after a dose is administered.


Q: What is the maximum duration of treatment with Fedyclar described in official literature?

A: Regulatory bodies state that Fedyclar is intended for short-term use to manage acute symptoms. Official regulatory documents advise that the medicine generally not be used for longer than seven days without professional oversight.


Q: Is it common to feel slightly different when first starting Fedyclar?

A: Regulatory tables show that certain documented adverse events, such as headache, dry mouth, or trouble sleeping, were reported by a significant percentage of patients during clinical trials. Feeling different initially may be due to these reported effects.


Q: Do most people who take Fedyclar experience side effects?

A: The incidence of reported adverse events is detailed in regulatory documentation, which indicates the percentage of clinical trial patients who reported specific reactions. For example, headache was reported by approximately 19% of patients, and insomnia by 16%.


Q: Does Fedyclar interact with common over-the-counter pain relievers?

A: Official regulatory guidance for the antihistamine component of Fedyclar, Loratadine, indicates that it can generally be taken alongside common non-opioid pain relievers like paracetamol or ibuprofen. However, the full interaction profile is complex. It is important to review the full interaction profile, including any over-the-counter products, with a health professional.


Q: Can Fedyclar be taken with vitamins or dietary supplements?

A: Official guidance includes the recommendation that patients review the use of all vitamins and supplements with a health professional, as some substances may affect how the body processes the drug. Specific herbal supplements, like St. John's wort, are often advised to be avoided due to potential drug interactions.


Q: Is Fedyclar suitable for older adults?

A: Regulatory pharmacokinetics documents indicate that exposure to the drug components, which measure how much drug is in the body (AUC and Cmax), may be increased in older adults compared to younger subjects. This is a factor considered when determining eligibility.


Q: Are there specific food items that interact with Fedyclar?

A: Official documents note that taking Fedyclar with food increases the amount of Loratadine absorbed into the body and delays the time it takes to reach peak concentration. Beyond the general effect of food, regulatory sources do not typically list specific dietary items that must be restricted.


Q: Has Fedyclar been studied for use in children or adolescents?

A: While the medicine is officially approved for use in adolescents aged 12 years and older, studies have also been conducted on the drug's components in younger age groups to understand how the drug is processed by the body in different populations.


Q: What is the difference in composition between brand-name Fedyclar and its generic form?

A: Regulatory bodies require that the active ingredients in any generic version of Fedyclar (Loratadine and Pseudoephedrine) must be chemically identical to those in the brand-name product. This ensures that the generic and brand-name products contain the same medicinal substance.


Q: Can Fedyclar affect driving or operating machinery?

A: Side effects documented in regulatory sources include dizziness and drowsiness. These effects may impair a patient's ability to safely perform tasks that require mental alertness, such as driving or operating machinery.


Q: Why do official documents advise taking Fedyclar at a certain time of day?

A: The specific dosing frequency (e.g., once daily or every 12 hours) is determined by the extended-release (ER) dosage form. This form is specially engineered to provide sustained drug concentrations over a prolonged period, such as 24 hours.


Q: Is Fedyclar known to cause weight gain or loss?

A: Regulatory documents list weight gain as one of the reported adverse events. However, its frequency is often classified as 'incidence not known' from available data, meaning the frequency cannot be reliably estimated.


Q: Does Fedyclar have any potential effects on mood or mental state?

A: Documented effects involving the central and peripheral nervous systems include nervousness, insomnia, and restlessness. Less frequently, official safety tables list problems with memory or concentration as reported adverse events.


Q: What is the recommended procedure if a dose of Fedyclar is missed?

A: Official instructions state that if a patient misses a dose, they should take it when they remember. However, regulatory documents establish the constraint that the maximum recommended dose (e.g., one dose) must not be exceeded within a 24-hour period.


Q: Does Fedyclar interact with birth control medication?

A: Official drug interaction databases for the active components (Loratadine, Pseudoephedrine) do not typically list an explicit interaction with hormonal birth control medications.


Q: How quickly does the drug Fedyclar leave the body?

A: Pharmacokinetic studies show that the drug components have a mean elimination half-life, which measures how quickly half the drug is cleared from the body. Loratadine has a mean half-life of approximately 8.4 hours, and its primary active metabolite around 28 hours.


Q: Can Fedyclar be taken with herbal remedies like St. John's Wort?

A: Specific herbal remedies, such as St. John's wort, are often advised to be avoided. This is because they may affect the enzyme systems in the body that are responsible for processing the drug’s components.


Q: What happens if Fedyclar is accidentally taken more often than advised?

A: In cases of accidental overuse, there is a potential for serious symptoms involving the cardiovascular system (e.g., fast heart rate) and the central nervous system (e.g., dizziness). The potential outcomes underscore the importance of seeking immediate medical assistance in such circumstances.


Q: Does Fedyclar affect fertility?

A: Official information based on the components of Fedyclar indicates there is no current evidence to suggest that the drug affects fertility in men or women.


Q: What is the official safety classification of Fedyclar?

A: Regulatory documents classify the drug’s components, with the antihistamine component (Loratadine) typically categorized by the FDA as Pregnancy Category B. The combination product itself has specific warnings for use during pregnancy that should be reviewed.


Q: Why might the effects of Fedyclar vary between different individuals?

A: Official pharmacokinetic studies indicate that the rate at which the drug's components are eliminated from the body varies widely among different individuals. This variability in the mean elimination half-lives is one factor that can influence how long the effects of the medication last for a person.

How should Fedyclar be stored and disposed of?

How to Store and Dispose of Fedyclar

The storage and disposal requirements for Fedyclar are defined by official drug labeling to maintain product stability and safety. The tablets must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F).

Storage Requirements

  • Protection: Keep the medicine out of the sight and reach of children and protected from light and moisture. Do not allow the tablets to freeze.
  • Container: Store Fedyclar in its original container, tightly closed. Do not use the medicine if the packaging is damaged or tampered with.
  • Handling: The extended-release tablet must not be crushed, divided, chewed, or dissolved.

Disposal

Disposal of unused or expired Fedyclar must be done in accordance with local regulations and guidance from a healthcare professional. The medicine should not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fedyclar  found in:

A-Z Index: